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The tumor microenvironment (TME) is a complex meshwork of extracellular matrix (ECM) 









(CAFs), blood vessel associated smooth muscle cells, pericytes, endothelial cells, 
mesenchymal stem cells and a variety of immune cells. 
In tumors the homeostasis governing ECM synthesis and turnover is disturbed resulting in 
abnormal blood vessel formation and excessive fibrillar collagen accumulations of varying 
stiffness and organization. The disturbed ECM homeostasis opens up for new types of 
paracrine, cell-cell and cell-ECM interactions with large consequences for tumor growth, 
angiogenesis, metastasis, immune suppression and resistance to treatments. As a main 
producer of ECM and paracrine signals the CAF is a central cell type in these events. Whereas 
the paracrine signaling has been extensively studied in the context of tumor-stroma 
interactions, the nature of the numerous integrin-mediated cell-ECM interactions occurring in 
the TME remains understudied. In this review we will discuss and dissect the role of known 
and potential CAF interactions in the TME, during both tumorigenesis and chemoresistance-
induced events, with a special focus on the “interaction landscape” in desmoplastic breast, 
lung and pancreatic cancers. As an example of the multifaceted mode of action of the stromal 
collagen receptor integrin 111, we will summarize our current understanding on the role of 













ABCG2 ATP Binding Cassette Subfamily G Member 2 
ADAM12 A disintegrin and metalloproteinase domain-containing protein 12 
αSMA Alpha-smooth muscle actin 
CAFs Cancer-associated fibroblasts 
CAF-S Cancer-associated fibroblast subset type 
cCAFs Cell cycle cancer-associated fibroblasts 
CAV1 Caveolin-1 
CD10 Cluster of differentiation 10, membrane metallo-endopeptidase 
(MME) 
CD29 Cluster of differentiation 29, integrin 1 
CD49c Cluster of differentiation 49c, integrin 3 subunit 
CD49e Cluster of differentiation 49e, integrin 5 subunit 
CD51 Cluster of differentiation 51, integrin v subunit 
CD105 Cluster of differentiation 105, endoglin 
CD126 Cluster of differentiation 126, interleukin 6 receptor 
CLCF1 Cardiotrophin-like cytokine factor 1 
CLU Clusterin 
CSC Cancer stem cell 
dCAFS Developmental cancer-associated fibroblasts 
dcn Decorin 
DDR2 Discoidin domain receptor 2 
DPP4 Dipeptidylpeptidase 4 
ECM Extracellular matrix 
EMT Epithelial-mesenchymal transition 
EndoMT Endothelial-mesenchymal transition 
ER Estrogen receptor 
ERK Extracellular signal-regulated kinase 
FAK Focal adhesion kinase 
FAP Fibroblast activation protein 
FGF Fibroblast growth factor 
FSP-1 Fibroblast specific protein-1 
GFPT2 Glutamin-fructose-6-phosphate transaminase 2 
GLI1 Glioma-associated oncogene homologue 1 
GPR77 G protein-coupled receptor 77 
HER2 Human epidermal growth factor receptor 2 breast cancer subtype 
HGF Hepatocyte growth factor 
Hh Hedgehog 
iCAFS Inflammatory cancer-associated fibroblasts 
IGF Insulin-like growth factor 
IGFBP3 Insulin-like growth factor-binding protein 3 




IRAK-4 Interleukin-1 receptor-associated kinase 4 
KPC KrasLSL.G12D/+; p53R172H/+; PdxCretg/+  































LTBP3 Latent transforming growth factor beta binding protein 3 
LOXL1 Lysyl oxidase-like 1 
LOXL2 Lysyl oxidase-like 2 
mCAFS Matrix cancer-associated fibroblasts 
MAPK 
MDSCs 
Mitogen-activated protein kinase 
Myeloid-derived suppressor cells 
MMTV Mouse mammary tumor virus 
MRTF Myocardin-related transcription factor 
MSCs Mesenchymal stem cells 
myCAFS Myofibroblastic cancer-associated fibroblasts 
NF Normal fibroblast 
NG2 Neuron-glial antigen 2 
NSCLC Non-small cell lung carcinoma 
PDAC Pancreatic ductal adenocarcinoma 
PDGFRα Platelet-derived growth factor receptor alpha 
PDGFRβ Platelet-derived growth factor receptor beta 
pFAK Phosphorylated focal adhesion kinase 
P-GP P-glycoprotein 
PyMT 
PTEN                                
Polyoma middle T 
Phosphatase and tensin homologue 
RTKs Receptor tyrosine kinases 
RTKIs Receptor tyrosine kinase inhibitors 
SCC Squamous cell carcinoma 
SMOi Smoothened inhibitor 




Transcriptional coactivator with PDZ-binding motif 
Tumor-associated macrophage  
TGFβ Transforming growth factor beta 
TNBC Triple negative breast cancer subtype 
TME Tumor microenvironment 
vCAFS Vascular cancer-associated fibroblasts 
WISP2 WNT1- inducible signaling pathway protein2 














The fibroblast is a cell type of paramount importance for extracellular matrix (ECM) 
production and remodeling in interstitial tissues[1]. Fibroblasts are central in wound healing, 
tissue fibrosis and tumor fibrosis and studies of molecular mechanisms have demonstrated 
that fibroblasts use similar “toolkits” to remodel the ECM in these different conditions [2-4]. 
In tumor biology the activated fibroblasts, often called cancer-associated fibroblasts (CAFs), 
act in the realms of the tumor microenvironment (TME) with consequences for tumor growth, 
formation of stem cell niches, immunosuppression, metastasis and chemoresistance[5,6]. In the 
current review we will focus on this important compartment of the tumor and discuss how 




In medicine, desmoplasia is the growth of fibrous or connective tissue. It is also called 
desmoplastic reaction to emphasize that it is secondary to an insult. Desmoplasia may occur 
around a neoplasm, causing dense fibrosis around the tumor, or scar tissue (adhesions) within 
tissues. 
 
The complexity of tumor microenvironment in different tumor types is overwhelming and 
therefore we have decided to limit ourselves and try to give an overview of the role played by 
CAFs in cell-ECM and paracrine interactions in the TME of three desmoplastic tumor types: 
breast, lung and pancreatic cancer. We will summarize some interesting new developments 
(without any claims to cover all new interesting findings), including data suggesting that 






Fibroblast- A poorly defined cell type of mesenchymal origin, which is non-vascular, non-
inflammatory and non-epithelial. Fibroblasts play a major role to produce fibrillar collagens 
and other interstitial ECM components and to take active part in matrix remodeling via 
integrins and release of matrix metalloproteinases during tissue regeneration events[1,5]. The 
transcriptional profile of fibroblasts varies with the anatomical location[11]. Cell lineage 
tracing in mouse has clarified distinct origins of fibroblasts in the heart and skin. Mouse 
cardiac fibroblasts are derived from epicardium or endocardium[12] and a common 
multipotent progenitor of reticular and papillary skin fibroblasts has been identified in mouse 
skin where neonatal fibroblast subtypes are characterized by a dynamic biomarker expression 
pattern [13,14]. Further heterogeneity in skin fibroblasts is introduced by presence of hair 
follicles, different embryonic origins of dermal fibroblasts in face (neural crest), anterior part 
(lateral plate mesoderm) and the posterior part of body (dermomyotome). Closer examination 
of dermal fibroblasts comparing human and mouse skin confirms the dynamic expression of 
biomarkers in human dermal fibroblasts and identifies differences in biomarker expression 
between mouse and human dermal fibroblasts[15]. Several groups have defined multiple 
subtypes of human skin fibroblasts[15-17] and a protocol to isolate reticular and papillary 









has identified six subtypes of fibroblasts [19] and in years to come additional tissue-specific 




Myofibroblast- An activated fibroblast considered to be contractile due to expression of the 
contractile isoform of actin, alpha smooth muscle actin (SMA)[20,21]. In some tissues 
known to express v1 integrin with a central role in TGF- activation in fibrotic 
conditions[22]. After completed wound healing myofibroblasts are usually depleted via 
apoptosis[21,23]. Mouse cardiac myofibroblasts have been observed to turn off SMA 
expression in the heart and form a cell type called matrifibrocyte with different properties 
than the undifferentiated pre-myofibroblasts[24]. Current data thus suggests that 
myofibroblasts display  more plasticity than previously thought. The finding that subsets of 
mouse skin myofibroblasts under certain conditions can differentiate into adipocytes further 
stresses the plasticity of myofibroblasts[25].  
 
Cancer-associated fibroblasts (CAFs)- Fibroblast-like cells, of different origins, present in 
the TME. Sometimes used as abbreviation for carcinoma-associated fibroblasts, to 
specifically denote cells associated with epithelial-derived tumors. Demonstrated to be 
surprisingly heterogeneous. A number of CAF subtypes have been defined within tumor 
stroma. Pioneer work has defined two major types of fibroblasts in pancreatic cancer, 
inflammatory CAF (iCAFs) and myofibroblastic CAFs (myCAFs)[26], and four major 
subclasses of CAFs in breast cancer (CAF-S1-S4), distinguished by different levels of 
SMA and fibroblasts activation protein (FAP) expression [27,28]. Due to plasticity and 
dynamic nature it has been suggested that the CAF subtypes do not represent fixed cell types, 
but rather represent fibroblast “states”[29]. Epigenetic changes do however result in more 
stable phenotypes[30,31]. Indirect evidence suggests that some subpopulations of CAFs are 
tumor-supportive whereas others are tumor-suppressive[32,33]. Demonstrated to act in a 
paracrine manner to affect different aspects of tumorigenesis, and via matrix synthesis and 
matrix remodeling to induce stiffness and hypoxia, which in turn also affect tumor growth. 
  
Major challenges in all forms of fibrosis include characterizing the degree of fibroblast 
heterogeneity, defining the origin of pro-fibrotic cells (also the potential targets of anti-
fibrosis therapy), and characterizing the dynamics of different biomarkers, which can be used 
to follow the fibrotic process as well as serve as potential therapeutic targets. 
Gene technology developments have helped to clarify some of the issues related to the origin 
of fibroblasts in animal fibrosis models. In several experimental systems, cell lineage tracing 
has thus clarified “muddy waters” where epithelial to mesenchymal transition (EMT) and 
fibrocyte invasion were suggested to contribute significantly to fibrotic processes.  The 
genetic-method based cell lineage tracing, often contested earlier immunohistochemistry-
based studies (typically relying on antibodies with unclear specificity or reactivity) and 
instead showed major roles played by tissue myofibroblasts derived either from endogenous 
resident fibroblasts[12,13,34], pericytes[35,36] or Gli+-positive mesenchymal stem cells 
(MSC)[37]. Pericytes exist as a major cell type in pancreas and in liver in the form of stellate 
cells[38,39], which in fibrosis models become activated to myofibroblasts and in tumors into 
CAFs. The relative contribution of pericytes to fibrotic stroma in tissues like kidney, lung and 
breast is complex[40] and will need careful cell lineage tracing in different mouse models. 
Heart and skin are two examples where resident endogenous fibroblasts are major sources of 









role in tissue fibrosis[37]. In the developing mouse heart EMT and endothelial mesenchymal 
transition (EndoMT) do play a role, but not in fibrotic conditions [12].  
As just mentioned, cell lineage analysis has thus clarified the origin of fibroblasts in skin and 
heart[12,13]. During scarring in the skin after injury or in heart after an infarction, endogenous 
fibroblasts migrate in and fill up the damaged area. The dynamics of the in-migration of two 
major types of fibroblasts in the wounded mouse skin occurs in two waves [41]. In a careful 
separate study these fibroblasts were further characterized into a “PDGFRhigh subset” and a 
“PDGFRlow subset”, which could be further subdivided into a several clusters [14]. As 
wounding is complete, wound fibroblasts disappear via apoptosis. In mouse skeletal muscle 
and skin ADAM12+/PDGFR+- perivascular cells appear to play an important role in tissue 
repair[36]. Recent data also demonstrate a role of Gli+ MSC in dermal wound healing[37]. 
In the heart the interstitial fibroblasts fill up the damaged area and during the repair phase 
express alpha smooth muscle actin (SMA) and are contractile. Interestingly, these 
fibroblasts then loose SMA expression and become quiescent [24]. Similar to the wound 
response in skin, Gli+ MSCs have been shown to contribute to cardiac fibrosis [37]. 
 
2.1 Tumor fibrosis 
Major factors that drive tumor desmoplasia include: autocrine and paracrine signaling of 
growth factors, cytokines and chemokines. These factors affect cell proliferation and 
migration as well as CAF-mediated ECM protein secretion and crosslinking of fibrillar 
collagen matrices that eventually lead to increased tissue stiffness and hypoxia [4]. 
Furthermore, ECM reorganization and ECM remodeling are determinant factors that affect 
the properties of the TME. 
Just as the origin of myofibroblasts in fibrosis varies, so does the origin of CAFs. Major 
sources of CAFs are the endogenous tissue fibroblasts, pericytes and ADAM12+ perivascular 
cells[4,36,42]. Applying cell lineage tracing methods in the polyoma middle T (PyMT) mouse 
model have demonstrated the contribution of mesenchymal, non-hematopoietic bone marrow 
cells to a PDGFR-, clusterin+- breast cancer CAF subpopulation (see 4.1 below)[43]. EMT 
contribution to CAF generation appears to be limited and EMT in the TME seems to be more 
involved in forming an invasive mesenchymal tumor cell type and in creating a niche for 
cancer stem cell formation[44]. However, active EMT processes in the tumor have indirect 
consequences for the stroma. In a recent study, EMT was studied in some detail in a genetic 
model Kras LSL-12GD/ p53 fl/fl /Lgr5CreER of squamous cell carcinoma (SCC) where tumors 
undergo spontaneous EMT[45]. These studies convincingly demonstrated that EMT occurs in 
stepwise manner leading to the generation of subpopulations of tumor cells in different 
intermediate states between epithelial and mesenchymal. Interestingly, as cells progressed 
towards EMT[45], the stroma changed in parallel, with regard to composition, presence of 
immune cells and localization. Most likely these changes are in part due to changes in the 
paracrine signaling of tumor cells undergoing EMT. A recent study also suggest that great 
care has to be taken when analyzing cells in invasive breast cancer[46]. Westcott et al studied 
the process of invasion and identified a switch of tumor cells state into a mesenchymal 
invasive state without the tumor cells actually undergoing EMT. The invasive cells leading 
the way in this initial invasive migration, so called trailblazer cells, were characterized by a 
mesenchymal seven gene signature composed of DOCK1, ITGA11, DAB2, PDGFRA, VASN, 
PPAP2B and LPAR1[46].   
When trying to map the heterogeneity of tumor stroma, it is thus important to distinguish 
CAFs from: 1) cells undergoing EMT and expressing a variable degree of mesenchymal 
biomarkers, 2) trailblazer cells with a mesenchymal signature or 3) mesenchymal stem cells 











2.2 Cell surface markers/biomarkers for fibroblasts, myofibroblasts and CAFs: 
Expression and biological function 
Multiple reviews have focused on the different biomarkers, which are useful when studying 
the TME. For simplicity we think it is convenient to categorize the biomarkers into membrane 
proteins, cytoskeletal proteins, intracellular proteins and nuclear proteins. For excellent 
reviews of the different biomarkers we refer to [5,47,48]. We would just like to add a few facts 
as reminders of uses and pitfalls for some of the relevant CAF markers. 
 
2.2.1 Membrane proteins 
 
Integrins: We will divide the discussion into different subfamilies, the major ones involved 
on tumor stroma belonging to 1- or v-integrin subfamilies (Fig.1, Table 1).  
1 integrin subfamily: The integrin heterodimers, which have emerged as candidates on 
CAFs to execute 1 integrin functions include 31, 51, 111 and v1. v1 will be 
discussed under v integrin subfamily. 
 1 integrin subunit (CD29): The integrin 1 subunit is shared by 12 different 
integrin heterodimers and is present on all nucleated cells [49]. The 1 subunit is expressed in 
excess compared to integrin chains in an intracellular pool. Cell surface expression of 
integrin  heterodimers containing CD29 is determined by integrin  chain expression. Due 
to the ubiquitous expression extreme care has to be taken when using CD29 as a CAF 
biomarker. Down-stream targets of 1 integrin signaling include the soluble tyrosine kinase 
FAK and the autophosphorylated FAK tyrosine residue Y397, as a general marker of active 
1 integrin signaling[50]. In addition to this role of FAK in integrin outside -in signaling it has 
also been demonstrated to take part in adhesion strengthening and affect myofibroblast 
differentiation in an unforeseen manner[51,52]. [53].  
 3 integrin subunit (CD49c): Integrin with wide expression on cells in contact with 
basement membranes[49]. 31 binds different laminin isoforms[49]. In CAFs, first reported 
to be involved in facilitating tumor cell migration in a mixed artificial matrix composed of 
laminin-111 and collagen I[54]. 31 has later been shown to bind laminin-332 in pancreatic 
ductal adenocarcinoma (PDAC) CAFs and facilitate cell migration of PDAC cancer cells[55].  
 5 integrin subunit (CD49e): Stromal integrin expressed on variety of cell types such 
as fibroblasts, endothelial cells, immune cells[56] and CAFs[57]. CAF integrin 51 is 
involved in assembly of fibronectin[58] and in enabling v3-mediated directional prostate 
and pancreas tumor cell migration[59]. In colon cancer 51 on CAFs cooperate with v3 to 
assemble fibronectin[60]. In a separate study it is shown that fibronectin-bound 51 integrin 
promotes tension-dependent malignant transformation through engagement of the synergy site 
that enhances integrin adhesion force. Ligation of the synergy site of fibronectin permits 
tumor cells to engage a zyxin-stabilized, vinculin-linked scaffold that facilitates nucleation of 
phosphatidylinositol (3,4,5)-triphosphate at the plasma membrane to enhance 
phosphoinositide 3-kinase (PI3K)-dependent tumor cell invasion[61]. The effect of fibronectin 
synergy site ligation by CAF 51 is unknown. In a careful study of PDAC CAFs in 3D 
environment 51 subcellular localization (and hence also activity) was controlled by v5 
in a complex manner [57].  
 11 integrin subunit: Integrin11 is expressed on subsets of fibroblasts and 
mesenchymal stem cells [62-66]. Expression on subsets of stromal cells needs to be better 
characterized and is ongoing. Data obtained so far, based on studies of PDAC and head and 
neck squamous cell carcinoma (HNSCC), have failed to demonstrate co-expression of NG2 in 









mesenchymal stem cells, 11 expression correlates with osteogenic potential of these cells 
[62]. Recent screening of tumor tissue array reveal expression of 11 in CAFs in multiple 
solid tumors[67]. Studies using animals deficient in 11 expression in the tumor stroma reveal 
major attenuation of tumor growth and metastasis in non-small cell lung cancer and breast 
cancer in the absence of 11 [8,10,68].  
 v (CD51) integrin subfamily: The integrin v chain dimerizes with different  
integrin chains. v6 is an epithelial integrin and is in tissues like lung and kidney involved in 
activating TGF-β (via binding of RGD in LAP-TGF-complex) in fibrosis[69]. Overall, 
whereas the understanding of the role of v integrins in tissue fibrosis is increasing relatively 
little is currently known about the role of v integrins on CAFs in terms of tumor-stroma 
interactions. In the tumor context it is possible that the v6 on tumor cells could take over 
the activating role, resulting in TGF--dependent CAF activation[70]. v1 in myofibroblastic 
cells is involved in TGF- activation in the context of fibrosis[22]. It is likely that v1 has 
similar orchestrating role for tumor fibrosis in different types of CAFs[70]. No antibody 
specific to the v1 dimer exists, and expression of this integrin needs to be verified 
biochemically in immunoprecipitation studies[22]. In vitro studies suggest similar roles for 
v3 and v5 in TGF- activation on myofibroblasts, but in fibrosis models v1 seems to 
play a major role. v8 is an interesting integrin, which use MMP-14 as the mechanism to 
activate TGF-[71,72]. v8 is expressed on different cells in the tumor. When expressed on 
tumor cells it helps tumor cells evade host immunity by regulating TGF- activation in 
immune cells [71,72]. As mentioned above v3 has recently been demonstrated to assist 
51 in fibronectin fibrillogenesis in CAFs to support directed cell migration[59]. 51 is the 
major receptor in mesenchymal cells for fibronectin assembly, but in early work on 1 -/- 
cells, v (in the absence of 51), was demonstrated to be relatively inefficient in 
assembling small and thick fibronectin fibrils in vitro [58]. It remains to be determined if the 
contribution of v3 to fibronectin assembly is a general feature of CAFs or a special feature 
of tissue-specific subsets of CAFs supporting metastasis.  
Fibroblast activating protein (FAP): FAP is a serine protease with post proline 
exopeptidase activity as well as gelatinase activity [73]. Initial studies of FAP expression 
suggested expression during development but only rarely in adult tissues. However, FAP is 
highly upregulated at sites of active tissue remodeling, including wound healing, fibrosis and 
cancer. More recent studies have shown that FAP expression in healthy tissues might not be 
as restricted as previously thought, which paradoxically becomes a major concern when 
targeting FAP (reviewed in [73]). Global deletion of FAP leads to impaired hematopoiesis and 
cachexia [74]. In the tumor context, in vitro studies suggest that FAP affects an inflammatory 
secretome including IL-6 and factors stimulating angiogenesis[73]. Together with other 
biomarkers it is a useful biomarker to identify CAF subsets, but FAP may be not the ideal 
target in therapeutic strategies.  
Cadherin-11: Classical cadherin expressed on multiple stromal cell types, including 
fibroblasts, macrophages and vascular smooth muscle cells. Increased expression on 
myofibroblasts (cadherin switch from expression of CDH2 to CDH11)[75]. One study has 
presented some evidence for an interaction between syndecan-4 and cadherin-11 and 
suggested that cadherin-11 regulates cell-matrix adhesion by binding syndecan-4[76]. This 
remains to be demonstrated in further studies but is certainly an interesting possibility. The 
role of cadherin-11 in skin and lung fibrosis has been suggested to be due to activation of 
TGF- signaling pathway[76-78]. Further support of a profibrotic role of cadherin-11 has been 
reported in studies of a homotypic cadherin-11-mediated interaction of macrophages and 









stability of the pro-fibrotic niche [79]. Cadherin-11 might be a useful marker for fibroblast 
subsets.  
PDGFR: PDGFR expression extends to multiple mesenchymal cell types. In addition to 
being expressed on pericytes it is also expressed on subsets of fibroblasts[80,81]. In a PyMT 
model of breast cancer PDGFR is expressed on bone marrow derived CAFs[43]. Careful 
studies have demonstrated prognostic significance of PDGFR in breast cancer[82-84]. The 
collaboration of PDGFR with 111 will be discussed in 4.2. 
PDGFR: A biomarker for fibroblasts that should probably not be used as a marker to isolate 
all subsets of fibroblasts in a tissue. In careful studies of cell heterogeneity in breast cancer 
and wound healing PDGFR is expressed on distinct subsets of CAFs and fibroblasts, 
respectively [43] Prognostic value of PDGFR expression has been studied in breast 
cancer[82,83]. Interestingly, bone marrow derived mesenchymal stem cells differentiated into 
CAFs in breast tumors of PyMT mice were distinguished from other CAFs by lacking 
PDGFR expression[43]. 
 
2.2.2 Cytoskeletal proteins and cytosolic proteins 
SMA (ACTA2): With increased awareness about CAF heterogeneity and the varying 
expression levels of SMA in different subsets of CAFs great care is needed when 
usingSMA as CAF marker for activated collagen-producing stromal cells [85].  
Vimentin: The cytoskeletal protein vimentin is often regarded as a general stromal marker, 
but in TME it is not only expressed in CAFs, it is also a major intermediate filament protein in 
endothelial cells in blood vessels. Curiously, resident MSCs have been reported to be 
characterized by low expression of vimentin [47].  
FSP-1: Fibroblast specific protein (FSP1; S100A4) is present in subsets of fibroblasts, but the 
expression in immune cells is a major concern when analyzing fibroblasts and CAFs[86-88]. 
With this in mind, studies using FSP1-Cre to delete CAFs probably has to be re-interpreted as 
it is becoming clear that it involves depletion of a subset of CAFs in addition to immune cells 
and other cell types[89]. 
 
2.2.3. Secreted proteins 
Tenascins: Tenascins constitutes a small family of related proteins. Tenascin-C in addition to 
being synthesized by CAFs is also secreted by tumor cells and it has been reported to be 
important for stability of tumor stroma niche[90,91]. Less is known about tenascin-W and 
tenascin-X in cancer, but in one study tenascin-X was shown to restrict melanoma invasion in 
a mouse model[92].  
Osteopontin: Osteopontin ca  be secreted by multiple cell types, including tumor cells 
themselves. Osteopontin have been shown to stimulate MSCs to assume a CAF phenotype via 
a TGF--dependent mechanism[93]. The characteristic secretion with a peritumoral 
localization is observed in multiple studies and suggest a special role for osteopontin in 
creating a cancer stem cell (CSC) niche[93,94].  
Periostin: Periostin is secreted by CAFs in different tumor types and suggested to concentrate 
Wnt ligands in stem cell niches[95].  
Clusterin: Clusterin (CLU) is an ubiquitously expressed heat shock protein and the secreted 
isoform is highly expressed in mammalian tissues and fluids[96]. The protein is a heterodimer 
composed by an α-chain and a β-chain. CLU may prevent uncontrolled membrane attack 
complex activity and thus play an important role to control terminal complement-mediated 
damage. Might have an important role on CAFs[43], but due to its wide expression predicted 










2.2.4 Role of CAFs in desmoplastic TME  
In the tumor stroma, CAFs interact with other cells and with the ECM to mediate CAF 
activation, tumor cell proliferation, directed cell migration and metastasis, to support stem cell 
niche generation, to regulate immunosuppression and to influence chemoresistance. Many of 
these aspects have been reviewed before (see [47,97,98]) and in this review we have chosen to 
place a special focus on the role of CAF interactions in desmoplastic tumors.  
 
As mentioned earlier cell-ECM interactions in the TME are understudied and we predict that 
this situation will change in the years to come. In future studies the role of integrins has to be 
understood in light of current knowledge of paracrine mechanisms in these tumor types. We 
have selected some recent publications that we think will be important to consider when 
elucidating integrin function in these tumor microenvironments.  The importance of taking 
this approach is illustrated by work in the PyMT breast cancer model where recent data have 
demonstrated a physical interaction of 111 integrin in a subset of CAFs with 
PDGFRresulting in signaling regulating tumor growth and metastasis[10]. We think that 
similar approaches will be fruitful when analyzing the role of integrins on CAFs in TME-
mediated chemoresistance where published work on cancer cells have demonstrated that 
integrins take an important part in chemoresistance mechanisms in response to tyrosine kinase 
inhibitors[99].  
 
Due to the complexity of collagen matrix in vivo and the tight packing into protein coated 
fibrils the actual availability of integrin binding sites in collagen fibril has come under 
question[100,101]. An emerging picture suggest that remodeling of the collagen fibril surface 
and proline-mediated flexibility maintains the integrity of the integrin binding sites[102,103]. 
However, the availability of integrin binding sites in fibrillar collagen in a remodeling 
actively synthesized matrix would be less of an issue. In this scenario, CAFs in an immature 
ECM where remodeling is still occurring would depend on direct binding to the collagen 
matrix via collagen-binding integrins, whereas in a more mature matrix, a switch would occur 
to indirect linkages to proteins like fibronectin via non-collagen binding integrins like 51. 
 
The role of the ECM in tumor growth (restraining or supportive) is still unclear but multiple 
studies suggest that a stiff linearized collagen matrix support tumor cell metastasis (see [104]). 
Landmark work by Sahai et al. has demonstrated that CAFs can pave the way for invading 
cancer cells, by drilling holes and reorganizing the matrix[54]. In the original studies 31 and 
51 were demonstrated to play this role in vulval CAFs migrating through an artificial 
mixed collagen I/laminin-111-containing matrix in vitro.  A recent publication in more detail 
analyze 31 on CAFs in PDAC, demonstrating that it interacts with laminin-332, mediates 
CAF differentiation and maintenance and supports PDAC cancer cell invasion[55].  
We will below summarize some interesting studies that are related to CAF-function in 
pancreatic-, lung-, and breast cancers and for each tumor type include examples of TME-
mediated chemoresistance. The role of cell-ECM interactions mediated by integrins in TME is 
largely understudied and constitutes an important area for future research. Wherever 
appropriate we have tried to highlight the potential importance of integrin mediated cell-ECM 
interactions in the TME, including potential role in chemoresistance, which as mentioned 













An increasing number of studies indicate the importance of the endogenous stroma in giving 
rise to CAFs. The complexity if the developmental origin of the endogenous stroma varies 
depending on the tissue. In pancreas two major potential stromal sources of CAFs are 
pancreatic fibroblasts and stellate cells. Stellate cells in the liver have been found to be of 
mesothelial origin and it has been suggested that pancreatic stellate cells are of 
neuroectodermal origin[105,106].  It is widely assumed that the pancreatic stellate cells are the 
major source of CAFs in PDAC, but this is clearly an area where our understanding is 
currently limited.  
In most models of tumor stroma interactions, a majority of published data suggests that the 
tumor stroma is tumor supportive[107,108]. This includes studies of pancreatic cancer, where 
stroma has been suggested to support tumor growth, tumor metastasis and to be involved in 
tumor chemoresistance[109]. With the increased awareness about CAF heterogeneity within 
TME many published studies might have to be revisited and the effects of TME re-examined 
in more detail, keeping in mind the CAF heterogeneity. This includes a widely cited paper 
from Ozdemir et al suggesting that conditional deletion of SMA-expressing fibroblasts in 
experimental PDAC worsened tumor outcome[110]. Experimentally SMA-thymidine kinase 
mice were crossed with two different models of PDAC, Ptf1acre/+ ; KrasGt2D/+ ;TGFbr2 flox/flox 
(PKT ) mice and LSLS-KrasG12D/+ ;Trp53R172H/+ ;Pdx cre/+ (KPC) mice, and cell depletion of 
SMA expressing cells was induced with ganciclovir. These rather drastic cell depletion 
protocols with reduced number of myofibroblasts resulted in more invasive, undifferentiated, 
and necrotic tumors. Notably, the use of ganciclovir for cell depletion also restricts the 
depletion to a not well-defined proliferating subset of SMA-positive cells. Interestingly, 
although reduced stiffness was observed in fibroblasts depleted tumors, LOX levels were 
unchanged. Furthermore, in the hands of Ozdemir et al., FAP and SMA did not co-localize 
in CAFs. In summary, this is a seminal study, which has received a lot of attention and raised 
the awareness about CAF heterogeneity. However, with more data accumulating from 
different experimental systems, especially with regard to CAF heterogeneity and SMA 
expression levels in different CAF subpopulations, some of the data might have to be re-
evaluated and re-interpreted.  
 Solid data is now accumulating on the heterogeneity of CAFs in different tumor types, 
including pancreatic cancer. In a careful study from Öhlund et al. [26], two major types of 
CAFs were identified both in the mouse KPC model and in human pancreatic cancer tissue. 
The CAFs identified peritumorally and expressing FAP and high levels of SMA, were 
denoted myofibroblastic CAFs (myCAFs). The myCAFs were found to need cell-cell contact 
to be induced to differentiate into this state. CAFs located at further distance from tumor cells 
and which expressed lower levels of FAP and SMA but secreting cytokines, like IL-6, were 
named inflammatory CAFs, iCAFs (Fig.2). The study also convincingly showed that CAFs 
can change from one state to the other (myCAFs to iCAFs and vice versa) in a dynamic 
manner. An interesting observation made in this study was that CAFs isolated from metastatic 
sites, unlike CAFs isolated from the primary tumor site, secreted a different cytokine 
repertoire (not including LIF and IL-11). It is possible that the different TMEs in the primary 
tumor and the metastatic tumor site contribute to the separate paracrine patterns. This agrees 
well with recent findings that CAFs in different tumors are distinct due to unrelated origins 
and deleting them result in discrete phenotypes due to different tissue contexts[5]. The 
findings in the study from Öhlund et al. have implications for the interpretation of the 
previously mentioned widely cited studies by Ozdemir et al. involving deletion of SMA 
expressing cells, which suggested that CAFs have a restraining role in pancreatic cancer[110]. 
It is for example possible that ablation of all cells expressing SMA, in addition to deleting 









potentially cause structural defects unrelated to depletion of SMA-expressing CAFs. The 
study from Öhlund et al. also raises the possibility that preferential deletion of myCAFs (high 
-SMA expressing) could have an effect different from deletion of the low -SMA 
expressing iCAFs. Further studies using new, more selective Cre-deleter strains will be useful 
to sort out this issue. With the availability of new tools, it will also be important to further 
categorize CAFs in pancreatic cancer further with additional biomarkers. Along these lines, a 
recent study has extended the use of markers and also divided the pancreatic tumor stroma 
into four domains[111]. The stroma in this study was divided into lobular stroma, septal 
stroma, peripheral stroma, juxtatumoral stroma. Regarding the biomarker expression patterns 
it is difficult to make correlations from this study to the study from Öhlund et al., since the 
authors find high SMA expression in all CAF subtypes. The authors however find increased 
levels of CD10 (a zinc-dependent cell surface associated metalloprotease), tenascin-C and 
mir-21 in the juxtatumoral stromal CAFs. CD10 is a new potentially interesting biomarker for 
CAFs. For now, the question is thus still open as to the specific role of the stroma in 
pancreatic cancer: tumor-supportive or tumor-suppressive? 
 
3.2  CAF integrins in pancreatic cancer TME 
In the context of PDAC, the importance of integrins is indicated in experiments where 
administration of FAK inhibitors left tumor angiogenesis, apoptosis and necrosis unaffected 
but reduced tumor size and the number of CAFs and tumor-associated macrophages (TAMs) 
within tumors[112]. To further determine the relative importance of TME integrins it would 
require conditional deletion of FAK or specific integrin chains in CAFs. The widely 
expressed integrin v3 has been implied in PDAC in a mechanism where CAF-produced 
osteopontin interacts with v3 on PDAC cells to stimulate EMT and cancer stem cell-like 
properties by modulating FOXM1 expression at the tumor stroma interface (Fig. 2) [113]. 
These osteopontin producing CAFs most likely correspond to the myCAFs mentioned above. 
Separate studies of human colon cancer have similarly demonstrated crucial interactions 
between a distinct subset of CAFs at tumor stroma interface interacting with osteopontin, 
which act by contributing to the formation of microenvironmentally defined cancer stem cells 
[114]. These data demonstrating intense signaling activity at stroma-tumor interface fit well 
with the findings that CAFs at tumor stroma interface in breast cancer and pancreatic cancer 
are distinct from CAFs elsewhere in the tumor[26,27].  
 
In support of a role of direct interactions of CAFs with collagen, a novel function-blocking 
antibody to integrin 11 can block PDAC CAF adhesion to collagen, collagen remodeling 
and spheroid invasion in a manner dependent on the total repertoire of integrin collagen 
receptors [67]. Based on immunohistochemical data with a commercial antibody to integrin 
11 combined with in vitro data involving PDAC CAFs, it is suggested that 111 indeed is 
a major integrin, which can stimulate PDAC cell invasion in an heterospheroid system [7]. 
Using a novel mono-specific monoclonal antibody to integrin 11, we can confirm that 11 is 
expressed on CAFs in PDAC tumor stroma in vivo, but in NG2-negative CAFs. It will be 
important to further study the role of 111 in PDAC to determine the origin of 11-
expressing CAFs using cell lineage tracing. In separate studies the role of fibronectin in the 
PDAC TME has been studied. Interestingly, it has been demonstrated that PDAC cells in a 3D 
collagen matrix migrate on elongated fibroblasts protrusions via cancer cell integrin 51 
adhering to fibronectin deposited on the fibroblast cell surface[115]. In a separate study v3 
integrin is suggested to be a colon cancer CAF integrin, which together with 51 is involved 









invasion[60]. It will be interesting to determine whether v3 has this function in different 
types of CAFs. 
 
As already mentioned, in a detailed study of PDAC CAF interactions with the 3D ECM it is 
elegantly demonstrated that v5 regulates endocytosis of 51 integrin and thereby also 
influencing myofibroblastic activation of these cells (Fig. 1) [57].  
 
The potential role of PDAC CAFs has been examined in relation to physiological laminin 
ligands where it is established that laminin-332 interacts with CAF 31 to support PDAC 
cell migration[55].  
 
To summarize the role of integrins on PDAC CAFs, current data suggest that 111 and 
51 are major integrins in matrix assembly and matrix reorganization involved in tumor cell 
growth and cell migration. v3 and v5 have both been found to assist or regulate the 
activity of 51 whereas little is known about cross-talk of 111 with other integrins in the 
PDAC context. In tissue fibrosis v1 integrin plays an orchestrating role by activating TGF-
 on myofibroblasts; it will be important to determine if it has a similar role on (a) particular 
PDAC CAF subtype(s). 
 
3.3 Paracrine signaling in pancreatic cancer TME 
Separate studies of genetic or pharmacological inhibition of Sonic hedgehog (Shh) in 
pancreatic CAFs revealed similar effects as Ozdemir et al. with undifferentiated tumors and 
decreased survival in mice as a results of the disturbed Hedgehog (Hh) signaling[116,117]. In a 
study by Pitaressi et al. the reason for this somewhat unexpected finding is clarified[118]. Hh 
signaling molecule Smoothened (Smo) in stromal cells lead to increased proliferation of 
PDAC cells, which could be linked to a RFN5 E3 ubiquitin ligase- mediated degradation of 
PTEN in Smo-null fibroblasts[118]. PTEN- deficient fibroblasts in turn were found to activate 
TGF-synthesis,which stimulated PDAC growth. Further studies of the mechanism 
suggested that hyaluronan synthesis is increased in PTEN-/- CAFs via increased activity of 
hyaluronan synthase 3 leading to decreased hydraulic permeability of the ECM. In support of 
this mechanism being relevant in PDAC disease, low stromal PTEN levels in PDAC patients 
correlated with poor overall survival. In conclusion, although data had suggested a role for Hh 
signaling as a target pathway in PDAC therapeutics, experimental data now paint a picture of 
complex tumor-stroma cross talk in pancreatic cancer involving Hh. Another recent example 
of the importance of stroma CAFs involves a pancreatic cancer model and Panc02 cells. In 
this model PDGFR-positive CAFs were found to produce IL-33, recruit TAMs and promote 
their differentiation into M2 macrophages[119] (Fig.2, Table 2). IL-33 in turn stimulated the 
synthesis of MMP-9 by TAMs, which has been suggested to be a major factor promoting 
metastasis from microvessels. This is an interesting experimental model and it would be 
interesting to trace these CAFs and analyze the dynamics of the changing integrin repertoire 
during tumorigenesis. During metastasis CAFs have been described to accompany the tumor 
cells[120], but so far no similar association between tumor cells and TAMs have been 
described; this is a possible scenario worthy of further investigation. In an interesting study, 
single-cell RNA sequencing of PDAC cells co-cultured with CAFs identified PDAC 
subpopulations with proliferative (PRO) or EMT hallmarks, which were confirmed in patient 
PDAC tumors [121]. In absence of CAFs, PDAC cells were mostly double-negative for these 
hallmarks, whereas PDAC with high CAF content were predominantly double-positive (DP), 









that CAF-secreted TGF-β1 drove the DP phenotype by activating the MAPK and STAT3 
signaling pathways in PDAC cells.  
 A central question in future studies will be to try and determine which are the tumor-
supportive and which are the tumor-suppressive types of CAFs in PDAC. Further studies of 
the paracrine signaling in myCAFs and iCAFs should also focus on integrin expression 
repertoire and the relative contribution of specific integrins to tumor-promoting and tumor-
suppressive CAF functions. It will also be important to determine whether different CAF 
subpopulations hold prognostic value and have different functional properties. 
 
3.4 TME-mediated Chemoresistance in pancreatic cancer 
Using orthotopic genetic animal models such as KPC models as well as biopsy material from 
pancreatic cancer patients, production of insulin-like growth factors (IGFs) by TAMs and 
CAFs have been demonstrated to contribute to TME-mediated chemoresistance[32,122]. In a 
study of Ireland et al., IGF receptors on tumor cell responded to IGFs by promoting 
proliferation and survival. Treatment with IGF-blocking antibody in combination with 
gemcitabine reduced tumor growth. Since integrins have been shown to crosstalk and 
associate with IGF receptors[123,124], it will be interesting to determine if they also contribute 
to IGF1R-mediated chemoresistance. Some pancreatic cancer tumors are characterized by 
increased activation of IL-1 receptor associated kinase 4 (IRAK-4) in the stroma. In these 
tumors CAFs and PDAC cells both contribute to IL1-production and IRAK4 
phosphorylation in a feedforward circuitry, resulting in fibrosis and chemoresistance[125].  
When IRAK4 is silenced in such experimental tumors the ability of CAFs and PDAC to 
promote fibrosis is reduced and the combined administration of IL1- antibody and 
gemcitabine increases the effect of chemotherapy. The extensive desmoplasia in pancreatic 
cancer is generally recognized as being a barrier for successful immunotherapy. Following the 
new data indicating an ever-increasing heterogeneity of CAFs, dynamic changes from one 
state to another, it is clear that we are beginning to appreciate the true complexity of the 
pancreatic tumor stroma. As we learn more, the chances also increase that we will reach a 
better understanding of the diverse roles of the pancreatic TME in chemoresistance. 
 
4. Breast 
4.1 CAF heterogeneity in breast cancer 
Breast is a complex organ, which undergoes hormonally regulated changes. In normal mouse 
breast the stroma largely determines glandular epithelium development.  Two subsets of 
mammary gland fibroblasts have been identified in human mammary gland, lobular 
(CD105high/ CD26low) and interlobular (CD105low/ CD26high) fibroblasts[126]. CAF 
heterogeneity in breast stroma has been identified in a study of human breast cancer[27] and in 
mouse models [43,127]. In the human breast study the authors classify four different subsets of 
CAFs, called CAFS1-CAFS4 using a combination of 6 different antibodies (Table 3).  
Notably, two of the subsets, CAF-S1 and CAF-S4 express high levels of SMA, but only CAF-
S1 expresses fair amounts of FAP. CAF-S1 is found close to the tumor, attracts T-cells and 
contributes to immunosuppression. On a cellular molecular basis, the immune suppressive 
function of CAF-S1 partly depends on dipeptidylpeptidase 4 (DPP4, also known as CD26) and 
DPP4-mediated cleavage of CXCL10, leading to a reduction in T-cell recruitment to the tumor 
(Fig. 2.). The careful study by Costa et al. [27] also indicates that within the four CAF 
subclasses there is probably even more heterogeneity. It is interesting to note that the CAF-S1 
display similar characteristics to the myCAF population in pancreatic cancer. However, 
whereas in pancreas the corresponding myCAF subset is thought to be pericyte-derived, it is 









Using single cell RNA sequencing, the issue of CAF heterogeneity was independently 
addressed in the MMTV-PyMT mouse model of breast cancer at late stages of tumor 
progression[127]. This study identified four transcriptionally distinct subsets of CAFs presenting 
different functionalities and biophysical properties. The four subsets of CAFs, termed as 
vCAFs (vascular CAFs), mCAFs (matrix CAFs), cCAFs (cell cycle CAFs) and dCAFs 
(developmental CAFs) presented distinct spatial location within the tumor parenchyma. vCAFs 
was shown to originate from the perivascular compartment with cCAFs being a segment of 
proliferative vCAFs. Conversely, mCAFs was shown to mostly derive from resident 
fibroblasts, while dCAFs seemed to originate from the malignant epithelial compartment via 
EMT. Interestingly, PDGFR was specifically expressed by mCAFs, whereas PDGFRwas 
expressed by all CAF subsets, with exception of dCAFs. In contrast to the previously 
mentioned study[27], FAP and αSMA markers were not specifically associated to a distinct 
subset of CAFs, but rather displayed a salt-and-pepper expression pattern in all four CAF 
subpopulations. These discrepancies are presumably related to breast cancer subtypes and 
stages, species differences and detection methodologies.  
As already mentioned, applying cell lineage tracing methods in the PyMT mouse model 
demonstrated the contribution of mesenchymal, non-hematopoietic bone marrow cells to a 
PDGFR-, clusterin+-breast cancer CAF subpopulation [43]. In vitro, bi-directional paracrine 
signaling between tumor cells and this subpopulation of CAFs had effects on both tumor cells 
and the CAFs. In this model clusterin, which has pleiotropic effects including stimulating 
endothelial cell proliferation, was suggested to promote tumor growth mainly via enhancing 
angiogenesis. This further highlights the complexity of fibroblast heterogeneity in breast cancer 
and suggests that this challenging issue requires additional investigation with regards to 
biomarker expression, spatial localization and functionality of these CAFs in all the subtypes 
and stages of breast cancer disease. 
 
4.2 Matrix receptors and desmoplasia in breast cancer; integrin 11 on CAFs 
One of the most notable features of tumor-stroma interactions in breast cancer is the 
desmoplastic reaction. Extensive desmoplastic reaction detected in normal breast tissue in form 
of mammographic density is strongly correlated to an increased risk of breast cancer 
development and has been proposed as a diagnostic and prognostic marker. Indeed, invasive 
ductal carcinomas often appear as a scirrhous mass of a stellate morphology caused by the high 
desmoplastic reaction observed in these tumors. The ECM composition and architecture 
associated to this fibrotic reaction emerge from an intimate crosstalk between fibroblasts and 
epithelial cells in breast tissues. Desmoplasia has also been linked to increased activation of 
integrins in breast cancer. In a breast cancer model, tumor secreted lysyl oxidase-like 2 
(LOXL2) activates fibroblasts and promotes the expression of SMA in a FAK-dependent 
manner[128]. A previous landmark paper has demonstrated that increased tumor stroma 
stiffness promotes tumor progression by 1 integrin signaling in a FAK and Rho-signaling 
dependent manner [50]. Likewise, in a mouse model of breast cancer, FAK inhibition decreases 
tumor growth and reduces infiltration of leukocytes and macrophages[129,130]. Together, these 
studies support the notion that 1 integrin and FAK sustains the pro-tumor functions of CAFs. 
 
From the perspective of CAF heterogeneity, the use of CD29 as a biomarker of CAFs in the 
study by Costa et al. [27] is interesting, since CD29 (integrin 1), is a common integrin  
subunit of 12 different integrin  heterodimers, and is thus widely expressed on all cells of the 
body[49]. Keeping this in mind, CD29 has limited use as a biomarker on its own, and even in 
combination with other markers, extreme care has to be taken when using high or low CD29 










The cooperation between integrins and receptor tyrosine kinase (RTKs) in tumor and stromal 
cells regulates cell invasion during metastatic dissemination in breast cancer. In this context, 
we have recently shown that stromal integrin α11 displays a pro-tumorigenic and pro-
metastatic activity in breast cancer and strongly associates with a PDGFRβ+ CAF subset 
(Fig.1) [10]. Integrin α11 expression is strongly upregulated in the stromal compartment during 
mammary tumor progression. Histological analyses revealed a strong association between 
integrin α11 and PDGFRβ, both in clinical breast cancer samples and in the pre-clinical 
transgenic mouse MMTV-PyMT model. Among several tested stromal markers (PDGFR, 
PDGFR, SMA, FAP, FSP1 and NG2), this collagen-binding integrin was mostly associated 
with a PDGFR+ CAF subpopulation at late stages of invasive tumors. As both integrin 11 
and PDGFR are well-known regulators of ECM, it is plausible that the identified CAF subset 
overlaps with CAF subpopulation described in the previously aforementioned study[127]. 
Indeed, genetic ablation of integrin α11 in the PyMT model drastically reduced not only tumor 
growth and metastasis, but also the desmoplastic reaction in these tumors, further highlighting 
the contribution of this specific11+ CAF subset to tumor progression through ECM 
regulation. This is further supported by the fact that mCAFs are thought to derive from resident 
fibroblasts, as well as integrin 11/PDGFR+ CAFs. Mechanistically, this study revealed that 
integrin 11/PDGFR crosstalk in CAFs endows breast cancer tumor cells with pro-invasive 
features through the deposition of tenascin-C (Fig.1, Table 2). Tenascin-C was strongly 
expressed by the same subset of CAFs expressing integrin 11 and PDGFR in the late stage 
PyMT tumors, as well as in clinical samples of invasive breast cancer. Overall, this study 
discloses an example of a collaborative crosstalk between an integrin and a growth factor 
receptor in CAFs, which acts as a driver of tumor invasiveness in breast cancer. Similar 
molecular partnerships have been previously reported, although not on CAFs. Indeed, 
microenvironment-induced c-Met/β1 integrin complex formation was shown to sustain breast 
cancer metastasis via the promotion of c-Met phosphorylation, as well as an increase of integrin 
affinity for fibronectin on the tumor cells[131]. Further examples of cooperation between 
integrins and growth factors receptors in the context of cancer are thoroughly discussed in 
previous reviews[132,133]. It is worth noting that 2 integrin subunit, which heterodimerizes 
with 1 integrin subunit to form another fibrillar collagen-binding integrin, exerts opposite 
functions to 111 in a related mouse breast cancer model. In contrast to α11 integrin chain, 
integrin α2 chain is expressed not only by CAFs, but also by tumor cells and other stromal 
cells. Furthermore, unlike integrin α11, the 2 subunit is downregulated in human breast cancer 
and acts as a metastasis suppressor in a murine model[134]. Indeed, α2-deficient MMTV-neu 
mice display increased metastasis, which is suggested to result from the increased capacity of 
tumor cells to intravasate into the bloodstream. These studies suggest opposite effects of two of 
the 1 integrin family members with affinity for collagen (α2β1 and α11β1) in breast cancer. 
 
Discoidin domain receptor 2 (DDR2) is a cell surface tyrosine kinase activated by collagens[5]. 
The function of DDR2 in both tumor cells and CAFs in a breast cancer model have been 
studied by perf rming global and tumor cell specific deletion of DDR2[135]. Global deletion of 
DDR2 does not affect primary tumor growth but results in reduced metastasis. Closer 
examination reveals that DDR2-/- stroma contains reduced amounts of fibrillar collagen, with 
reduced diameter and reduced organization (DDR2 CAF dependent function). DDR2 
expression in tumor cells in turn appears to contribute to collective tumor invasion, suggested 
to occur by DDR2-dependent stabilization of EMT factor SNAIL1. Since there is a certain 
amount of crosstalk between 1 integrins and DDR receptors it is possible that integrins, 
together with DDRs, in this model also are involved in tumor cell invasion and metastasis [136]. 









tumor-microenvironment interaction and tumor invasion[137]. It will be interesting to sort out a 
possible cooperation of DDR2 and integrins in tumor metastasis and whether such a link exists, 
identify the specific integrin(s) involved. 
 
In summary, an important cooperation between integrin and RTKs is detected in breast cancer 
CAFs, raising a number of interesting questions.  Future studies will for example determine if 
one and the same integrin can cooperate with different RTKs in different tumor stroma 
contexts or if the cooperation is integrin-specific and limited to some kinases. This also 
extends to mechanism of TME-mediated chemoresistance where data is emerging on the role 
of integrins in mediating chemosresistance to drugs targeting RTKs[99]. These mechanisms 
have mainly been described in cancer cells, but similar mechanisms are likely to operate in 
CAFs. Finally, the role of v integrins (TGF- activating mechanisms), 51 integrin and 
fibronectin matrix assembly, in relation to the collagen remodeling 111 integrin will be 
important to study more in detail in breast cancer, just as in other desmoplastic tumor types. 
 
4.3 Paracrine mechanisms in breast cancer TME 
In a now seminal paper, an important role of stromal cell-derived factor 1 (SDF1; released 
from CAFs) and the corresponding receptor CXCR4 (on breast cancer cells), in tumor growth, 
was demonstrated [138,139] (Fig.2). In a more recent study, using a mouse model for triple 
negative breast cancer (TNBC), monocytes and myeloid-derived suppressor cells (MDSC) 
were found to negatively affect survival, which was ascribed to their immunosuppressive role 
and effect on invasion and angiogenesis[140]. When analyzing the effect MDSCs on stroma 
formation it was found that these cells stimulated stroma formation by activating CAFs and 
by recruiting immunosuppressive myeloid cells. Curiously, this effect was specific for TNBC 
cells and not seen with other breast cancer types and found to be related to their synthesis and 
secretion of CXCL16. 
PDGF-BB-PDGFRβ signaling is one of the main pathways, which promotes the fibrotic 
reaction in cancer. In a paracrine manner, tumor and stroma-derived PDGFs activate PDGFRβ 
on CAFs and pericytes and promote ECM deposition and remodeling, increase the interstitial 
fluid pressure, sustain the angiogenic process and restrain the immune surveillance[141]. 
Stromal PDGFRs have been proposed for long-time as biomarkers for prognosis and response 
to RTK inhibitors (RTKIs) in cancer disease[83]. Previous works established that high 
PDGFRβ expression in CAFs and pericytes is associated with aggressiveness and poor 
prognosis in breast cancer [83]. Multivariate analyses revealed a positive correlation between 
high stromal and perivascular PDGFRβ expression and poor prognosis markers such as high 
histopathological grade, high proliferation, estrogen receptor negativity and HER2 
amplification[82,142]. Furthermore, increased serum PDGF level in breast cancer patients was 
positively correlated with disease prognosis and recurrence in breast cancer [143]. Elevated 
PDGFRβ stromal levels have been also related to impaired therapeutic response. A previous 
study revealed that breast cancer patients with low stromal and perivascular PDGFRβ 
expression benefit more from chemotherapeutic agents such as tamoxifen and epirubicin than 
patients with high PDGFRβ expression[84].  
Similarly, PDGF-CC-PDGFRα paracrine signaling has also been reported to contribute CAF-
cancer cell crosstalk in breast cancer. In a recent study, by using clinical specimens and a 
genetically MMTV-PyMT modified mouse model for PDGF-CC, the authors demonstrated 
that tumor epithelium-derived PDGF-CC induces a basal-like ER-negative phenotype, rather 
than a luminal ER-positive molecular phenotype of BC through the activation of CAFs[144]. 
These PDGF-CC-activated CAFs secrete pro-tumorigenic growth factors such as hepatocyte 
growth factor (HGF), insulin-like growth factor binding protein 3 (IGFBP3) and the secreted 









TME of PyMT tumors. Furthermore, genetic ablation and pharmacological inhibition of 
PDGF-CC resulted in a conversion of basal-like phenotype of breast cancer into a ER-positive 
state, which conferred sensitivity to tamoxifen therapy. This study highlights CAFs as 
functional mediators of the molecular subtype of breast cancer and as TME regulators of the 
therapeutic response to endocrine therapy. 
 
4.4 TME-mediated chemoresistance in breast cancer 
Hedgehog ligand activity is detected in one third of TNBC. In an animal model of TNBC with 
increased Hh levels, an increased production of fibroblast growth factor 5 (FGF5) and an 
increased collagen remodeling activity was observed in CAFs[145]. The increased 
concentration of remodeled collagen at tumor stroma interface correlated with increased 
pFAK levels as well as increased number of CSCs at the tumor-stroma interface. In this breast 
cancer model, treatment with the smoothened inhibitor (SMOi) sensitized mice to 
chemotherapy. It will be interesting to determine what specific integrins are present and 
mediate the increased pFAK at the tumor stroma interface.  
 Studies in breast and pancreas cell lines offer additional detail as to how CSC 
formation via EMT may occur. Snail1, which is a central transcription factor in EMT is an 
unstable protein that is ubiquinated. In experiments performed by Lambies et al., 
deubiquitination by a specific ubiquitinase (USP27X) contributes to Snail1 stability in turn 
contributing to increased EMT, increased amounts of CSCs and increased 
chemoresistance[146]. In addition, Snail1 stabilization in CAFs contributes to increased CAF 
activation. It will be interesting to see whether CAF Snail1 in this context integrates with 
integrin-dependent mechanoregulated signaling. Such mechanoregulation in myofibroblasts 
involving Snail1 has recently been shown to contribute to fibrosis and depend on both 
YAP/TAZ and MRTF transcription factors[147]. 
In an impressive study of breast cancer chemoresistant patients, CAF subsets were 
identified[6]. These CAFs expressed the usual markers, SMA, PDGFR, FAP, FSP1, but 
were distinguished by the expression of two additional cell surface markers CD10 (zinc 
metalloprotease) and GPR77 (anaphylatoxin receptor). In this careful study the activation of 
GPR77 by autocrine production of C5a lead to: 1) production of IL-6 which in turn increased 
the abundance of CSCs (by providing a survival niche for CSCs) as well as, 2) increased 
expression of the multidrug transporter ABCG2, largely responsible for the observed 
chemoresistance. The CD10+GPR77+ CAF subset thus sustained cancer stemness and 
promoted tumor resistance. Targeting this subset of CAFs furthermore restored 
chemosensitivity. The authors suggest that targeting the CD10+GPR77+ CAF subset could be 
an effective strategy against CSC-driven solid tumors. It will be interesting to relate this 
subset of CAFs with the different breast cancer CAF subsets identified by Costa et al., as well 
as with CAF subsets in other cancer forms [27]. It will also be important to characterize the 
role of integrins in TME-mediated chemoresistance in breast cancer.  
 
5. Lung 
5.1 Fibroblast heterogeneity 
The lung is also a complex organ where fibroblasts have a number of functions associated 
with normal lung function. Cell lineage tracing has been performed to identify and 
characterize the origin of fibroblast subsets[148], but in mouse lung, single-cell transcriptional 
analysis has been even more instrumental and has resulted in the identification of five subsets 
of fibroblasts in healthy lung and six subsets in fibrotic lung, in addition to a mesothelial 
subtype [19]. In normal lung these were grouped as myofibroblasts (Acta2+), col3a1 matrix 
fibroblasts (Col3a1+;Itga8+), Col4a1 matrix fibroblasts (Col4a1+;dcn+), lipofibroblasts 









cell type with high PDGFR expression, distinct from pericytes, was identified[19]. In non-
small cell lung carcinoma (NSCLC) stroma, high expression of PDGFRα is associated with 
better outcome in two independent patient datasets, while PDGFRβ expression differently 
affects patient's prognosis in the two cohorts [149]. In light of these findings, great care is 
needed when considering PDGFRs as NSCLC therapeutic targets. Whereas studies of 
pancreatic and breast cancer tumors have started to unravel different subsets of CAFs, less 
detailed information is published on CAF heterogeneity in NSCLC. In one interesting recent 
study the influence of vascular adventitial fibroblasts on A549 lung cancer cells in a xenograft 
model indicated a higher tumor-promoting activity of the adventitial fibroblasts compared to 
non-vessel associated lung fibroblasts[150]. Microarray analysis further demonstrated a high 
level of podoplanin expression in these adventitial fibroblasts, which in combination with 
other studies suggest a role for podoplanin in tumorigenesis and lymph node metastasis. The 
study by Hoshini et al. in addition to demonstrating CAF heterogeneity in the lung tumor 
stroma, suggests that a perivascular environment in lung constitutes a specific niche for tumor 
progression in the lung. Podoplanin expression has recently been shown to regulate 1 
integrin levels in keratinocytes[151], whether this activity also applies to NSCLC CAFs 
remains to be determined. Studies using FAP antibodies as a biomarker has also provided 
information, which clearly indicate the existence of CAF subsets in the lung[152]. 
Immunostaining of human NSCLC tumor sections in studies by Kilvaer et al. typically 
showed SMA and FAP expression on different CAFs, suggesting that in the lung FAP is not 
highly expressed on myofibroblastic CAFs. The study also points out a major weakness with 
FAP antibodies in the context of the TME; namely, FAP antibodies also immunostain 
macrophages. In tumors from NSCLC patients with high levels CD3+ and CD8+ T cells, high 
FAP levels on CAFs was associated with better prognosis. The latter finding indicates that 
FAP-directed therapy as a general anti-stroma therapy needs to be performed with great 
caution, and as already mentioned might not be suitable as a general anti-stroma therapy, but 
rather be suitable for a subset of tumors. That the general expression pattern of CAF markers 
needs great attention in therapy situations is also illustrated by experiments with FAP-directed 
immunotherapy where a side effect of the tumor directed treated therapy was cachexia, due to 
expression of FAP in muscle[74]. Finally, as yet another example of the complex events that 
take place in the TME, a recent study of a cohort of NSCLC patients identified glutamin-
fructose-6-phosphate transaminase 2 (GFPT2) in CAFs as being responsible for increased 
glucose uptake and metabolic reprogramming in the TME[153]. 
 
5.2 Integrins in lung cancer TME; the role of integrin 11 
In 2002 the Tsao laboratory published a list of 6 novel candidate genes for lung 
adenocarcinoma (obtained by comparing pooled RNA from tumors with normal lung RNA), 
which included Lc-19, HABP2, CRYM, CP, COL11A1 and ITGA11[154]. In 2011 Navab et al. 
published a molecular signature for the NSCLC stroma[155]. Paired matched lung normal 
fibroblasts and lung CAFs were isolated from 15 patients and their transcription profiles 
established. This effort resulted in identification of 46 differentially expressed genes in CAFs 
that formed a prognostic gene expression signature. Interestingly, six of the identified genes 
could be induced by TGF- in normal fibroblasts, including the collagen receptor 111, 
identified in the original gene set from 2002. Comparison of these CAF genes with tumor 
stroma genes indicated a shared upregulation of 4 genes; ITGA11, THB2, COL11a1 and 
CRTHRC1. In the same study analyses of epigenetic changes identified limited methylation 
changes in tested genes. Following the identification of 11 as one of a limited set of genes 
being upregulated in the stroma of experimental NSCLC tumors, the role of 11 in lung 
cancer was explored further. In xenograft models co-implantation of NSCLC tumor cells with 









this xenograft model was correlated to 11- dependent secretion of IGF-2. To functionally 
further test the potential contribution of 11 to CAF function in NSCLC the integrin 11-/- 
mouse strain has been very helpful[65]. Analysis of NSCLS tumor growth in the 11-/- mice 
demonstrated that absence of 11 in the stroma impeded NSCLC tumor growth[8] and 
metastasis. Analysis of tumor stroma demonstrated reduced organization of the collagen 
stroma and reduced tumor stiffness. Analysis of signaling status demonstrated reduced FAK 
and ERK phosphorylation in the tumor stroma from 11 -/- mice and reduced expression of 
SMA in the tumor stroma. Interestingly, integrin α11 has recently been shown to regulate 
the lysyl oxidase-like 1 expression in lung CAF to mediate NSCLC cell invasion and tumor 
growth [9] (Fig.1). Protein-protein interaction network analysis in addition identified a 
number of interactions affected in the 11-/- stroma and previously identified in CAF 
differentiation and tumorigenesis, including latent transforming growth factor beta binding 
proteins 3 and 4 (LTBP3 and 4), WNT1- inducible signaling pathway protein2 (WISP2), 
insulin-like growth factor binding protein 2 and 4 (IGFBP2 and 4) and syndecan-4. It will be 
interesting to determine whether, and how, these proteins take part in 11-mediated effects in 
CAFs and other types of stromal cells. 
 
5.3 Paracrine signaling in lung TME 
Separate gene expression studies in mouse lung CAFs compared with normal mouse lung 
fibroblasts identified a gene signature of upregulated genes in CAF, which could be used to 
predict survival in patients with NSCLC[156]. In this study 164 genes were identified, with 
little overlap with the Navab studies[155]. Functional studies furthermore identified a member 
of the IL-6 family, CLCF1, secreted from CAFs, as being pro-tumorigenic (Fig.2). IL-11, 
which has been found to work in a paracrine mode in tumor-stroma interactions in other 
models of lung cancer, was inactive in this model system[157]. The authors suggest that tissue 
specific factors determine interleukin isoforms and interleukin receptor subtype as 
determinants of paracrine signaling specificity in different tumor and tissue contexts. Most 
likely this pairing and switching of receptor subtypes introduced a molecular specificity is a 
strategy that might also apply to receptor-ligand pairs involved in cellular interactions with 
the ECM. 
 
That CAFs can regulate plasticity of lung cancer stemness via paracrine signaling was shown 
in experiments, which identified IGF-2 producing CAFs as inducers of Nanog expression in 
cancer cells and thus established that these lung CAFs constitute a supporting niche for cancer 
stemness [158]. With regards to IGF-2 it is interesting to note that the integrin111- 
expressing fibroblasts in the xenograft model of lung cancer produce IGF-2[68], and part of 
the pro-tumorigenic action of 111 might thus be related to a stemness-stimulating activity.  
 
5.4 TME -mediated chemoresistance in the lung 
Regarding studies of TME-induced chemoresistance in the lung, CAFs have been reported to 
produce IGF-2 as an inducer of the ABC transporter P-GP in A549 cells and to mediate drug 
resistance[159]. The proteoglycan serglycin (produced both by cancer cells and CAFs) and 
acting via CD44 on cancer cells has been reported to induce Nanog expression and to confer 
chemoresistance [160]. Lung adenocarcinoma CAFs treated with Cisplatin upregulate IL-11 
and confer chemoresistance to lung cancer cells by activating STAT3 anti-apoptotic 
pathway[157]. In agreement with these in vitro findings, patients with high levels IL-11R 
display poor response to Cisplatin. It will be important to relate these studies of 
chemoresistance to changes in cell-ECM interactions. As the paracrine signaling changes in 
response to chemotherapy it will thus be important to identify changes in integrin expression 












It is likely that next decade, new biomarkers, better antibody reagents, combined with new 
technical achievements, will lead to the identification of multiple subsets of CAFs in the 
context of breast-, lung- and pancreatic cancer. It will be important to characterize the role of 
integrins in these different subtypes of CAFs. Emerging data suggest an ever-increasing 
heterogeneity of CAFs, which most likely will be reflected in tissue- and subtype-specific 
modes of integrin actions in these different CAFs. Function-blocking integrin antibodies and 
conjugation of these into antibody-drug conjugates is likely to generate new treatment 
options, including alternatives that increase the efficacy of immunotherapy. One can thus still 
be optimistic that continued studies will ultimately present yet unknown biomarker and drug 
target opportunities in the integrin CAF landscape in the desmoplastic tumor stroma. We look 
forward to re-visit the tumor microenvironment research field in a decade and be amazed 




This work was supported by Norwegian Centre of Excellence grant from Research Council of Norway (ID 
223250), and MOTIF a Norway-North America grant from Norwegian Centre for International Cooperation in 
Education (SIU; PNA-2014/10057), a grant from ITN Marie Curie Actions FP7/2007-2013 (grant agreement 
n°316610, the Fondation contre le Cancer (foundation of public interest, Belgium), the Fonds spéciaux de la 
Recherche (University of Liège), the Fondation Hospital-Universitaire Léon Frédéricq (University of Liège) 


























Table 1. Summary of selected integrins with relevance for CAF function 
Overview of some integrins implicated in CAF function in desmoplastic tumor stroma. When integrin has multiple ligands, known stroma 
relevant ligands are underlined. +; low to moderate expression, ++; fair expression, +++; high expression. ?;ND. Note that estimations of 
expression levels are subjective estimations.  




     
31 
(CD49c) 
+ + ++, Vulval CAFs, PDAC CAFs: facilitate cancer cell 






+ + +++, Vulval CAFs, SCC CAFs: facilitate cancer cell 
migration, assembly of fibronectin 
fibronectin [54,161] 
111 + ++ +++, NSCLC CAFs, HNSCC CAFs, breast cancer CAFs, 
CAFs in multiple tumor types (in vivo), PDAC CAFS in 
vitro: collagen remodeling, CAF migration, paracrine 
signaling; synergize with PDGFR 




     
v1 + ++, lung, kidney, 
liver (in vivo): 
activate TGF- 
? Fibronectin, vitronectin, LAP-
TGF- 
[22,70] 
v3 + +, human dermal 
fibroblasts 
++, breast cancer, PDAC: TGF- activation ?, cooperate 
with 51 in organizing CAF fibronectin matrix, 
supporting directed cell migration of PDAC cancer cells, 




v5 + ++, human dermal 
fibroblasts 
++ , human PDAC CAFs : CAF activation, TGF- 
activation ?, cross-talk with 51 regulating endocytosis 
of 51 in PDAC CAFs.  
Vitronectin, LAP-TGF- [57,70,164] 
v8 +, lung ++, lung:  TGF- 
activation 
?,  In tumor stroma v8 expressed on T-cells and tumor 
cells. Activated TGF- can affect CAF synthesis of 
collagen I. 











Table 2. Selected molecular mechanisms of tumor-stroma interactions in breast cancer, pancreatic cancer and non-small cell lung 
cancer. Abbreviations: PDAC (Pancreatic ductal adenocarcinoma), PTEN (Phosphatase and tensin homologue), TAMs (Tumor-associated macrophages), iCAF 
(Inflammatory cancer-associated fibroblast), LOXL2 (Lysyl oxidase-like 2), PDGFR (Platelet-derived growth factor receptor beta), SDF1 (Stromal cell-derived factor 1), 






Model system Category of 
interaction 
Molecule Mechanism Refs 
Pancreatic 
cancer 
Human fibroblasts and CAFs from 
PDAC tumors. 
Cell surface Integrin 111 Integrin 111 mediates cell migration and matrix reorganization in PDAC CAFs. [7,67] 
 Mist1-KrasG12D; Smo loxP/-; FspCre mice Paracrine Shh/Smoothened/
TGF- 
Smoothened-/- stromal cells downregulate PTEN, leads to secretion of TGF- [118] 
 Il-33 -/-, Il-33-/-//SCID mice Paracrine Il-33 CAF-produced Il-33 recruits TAMs which stimulate metastasis. [119] 
 Col-Cre-ERT2 mice Paracrine Il-6, Il-11 iCAFs in tumor periphery express Il-6, Il-11, increase suppressive myeloid cells, 




Orthotopic model in mammary fat pads 
with shLOXL2 4T1cells 
Extracellular 
matrix 
LOXL2 Tumor-produced LOXL2 increases matrix stiffness, increases pFAK and SMA 
expression in fibroblasts. 
[128] 
 Itga11-/- //PyMT mice Cell surface Integrin 111 Present on CAFs, interacts with PDGFR to support CAF invasion, mediates 
metastasis. 
[10] 
 Ddr2-/-//PyMT mice Cell surface DDR2 Mediates metastasis, regulates CAF paracrine signaling. [137] 
 Primary CAFs from breast cancer 
patients. 
Cell surface FAP On myCAFs, immunosuppressive. [27] 
 Subcutaneous xenografts in nude mice Paracrine SDF-1 CAF-produced SDF1 binds CXCR4 on tumor cells [138,139] 




11-/- //SCID mice, 11 KD Cell surface Integrin 111 Expressed on CAFs mediates NSCLC growth via IGF-2 secretion, stiffness 
regulation. 111 integrin regulates LOXL1 levels. 
[8,68,166
] 
 Xenografts in SCID mice Paracrine IGF-2 CAF-produced IGF-2 induces Nanog in cancer cells. [158] 






















Table 3. CAF heterogeneity as revealed by differential expression of biomarkers in human breast cancer CAF subsets. Summary of expression of 
SMA, CAV1, CD29, FAP, FSP1 and PDGFR in representative breast cancer tumors. For specifics please go to [27] for details. 
CD29(integrin chain);SMA ( smooth actin); CAV1 (caveolin 1);  FAP (fibroblast activation protein); FSP1 (fibroblast specific protein 1) HER2 (human epidermal 





CAF-S1 CAF-S2 CAF-S3 CAF-S4 
 CD29 Med Low Med Hi 
FAP Hi Neg Neg Neg 
FSP1 Low-Hi Neg-Low Med-Hi Low-Med 
SMA Hi Neg Neg-Low Hi 
PDGFR Med-Hi Neg Med Low-med 
CAV1 Low Neg Neg-Low neg-low 
Myofibroblasts +++   +++ 
LumA  +++ + ++ 
HER2   + +++ 










Figure 1. Schematic illustration of CAF integrins interactions in three different forms of cancer. 
Integrins are transmembrane receptors that mediate cell interaction with the extracellular matrix (ECM). The Integrin family is composed of 18 α 
and 8 β subunits, which dimerize to form 24 distinct integrins with differential ligand specificity. The integrins described in this review have 
been highlighted. CAF integrins in lung tumor microenvironment (TME): Expression of integrin α11β1 on cancer-associated fibroblasts (CAFs) 
regulates ECM stiffness and remodeling and IGF-2 secretion, leading to metastasis and tumor growth of non-small cell lung cancer (NSCLC), 
respectively. In addition, integrin α11β1 regulates the lysyl oxidase-like 1 (LOXL1), which is an ECM cross-linking enzyme involved in tumor 
growth and invasion. CAF integrins in breast TME: Breast tumor cells releases PDGF-BB that activates PDGFRβ on CAFs. PDGFRβ interacts 
with integrin α11β1 to mediate metastasis. Integrin α5β1 collaborates with PDGFRα on CAF to align fibronectin matrices, which in turn support 
breast tumor cell invasion. This mechanism involves the myosin light chain 2 (MLC2). CAF integrins in pancreas TME: Release of TGF-β in 
pancreatic ductal adenocarcinoma (PDAC) induces the formation of a desmoplastic ECM by CAFs, which results in up-regulation of integrin 
α5β1 and αvβ5 at the CAF cell surface. Integrin αvβ5 mediates endocytosis of active integrin α5β1 that signals to activate myofibroblastic CAFs. 
Integrin α3β1 binds to laminin 332 to mediate CAF activation and maintenance and to support PDAC invasion. Integrin α11β1 regulates ECM 




















Figure 2. Schematic illustration of tumor-stroma interactions involving CAFs in three different forms of cancer. CAF in lung tumor 
microenvironment (TME): Glutamin-fructose-6-phosphate transaminase 2 (GFPT2) in CAFs is responsible for increased glucose uptake and 
metabolic reprogramming in the TME of non-small cell lung cancer (NSCLC) adenocarcinoma (ADC) to support tumor progression. IGF-2 
secretion also induces Nanog expression in NSCLC cells contributing to cancer stem cell (CSC) induction. CAF produces CLCF1 that increases 
NSCLC tumor growth. CAF in breast TME: CAF secretes SDF-1 that activates CXCR4 on breast tumor cells increasing tumor growth. CAF 
produces also CXCL16, recruiting monocytes that in turn activates CAFs. LOXL2 secreted by breast tumor cells regulates CAF activation and 
ECM stiffness and remodeling, leading to metastasis. DPP4 expressed on CAF dimerizes with FAP and interacts with the lymphocyte T 
regulators (Tregs) to suppress immune response. CAF in pancreas TME: Myofibroblastic CAFs (myCAFs) adjacent to pancreatic ductal 
adenocarcinoma (PDAC) may secrete osteopontin, which interacts with integrin αvβ3 on PDAC to support cancer stem cell induction. 
Inflammatory CAFs (iCAFs) at a further distance to PDAC secrete Il-6 to recruit Tregs and myeloid-derived suppressor cells (MDSCs), 
suppressing the immune response. CAFs secrete Il-33 to recruit tumor-associated macrophages (TAMs) that in turn synthesize MMP-9 to 
mediate PDAC metastasis. Inhibition of smoothened (Smo) and PTEN in CAF leads to TGF-α secretion to support PDAC tumor growth. Please 
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